It could be hypothesized that SSTR2 agonists, as shown in neuroendocrine tumor cells, also decrease HIF-α content in PPGL cells and are therefore especially effective in PPGLs with disruption of the Krebs cycle such as SDHx-related PPGLs. Here, SSTR2 is linked to neuroendocrine neoplasm.